In re Suboxone (Buprenorphine Hydrochloride & Naloxone) Antitrust Litigation
64 F. Supp. 3d 665
E.D. Pa.2014Background
- Direct Purchasers and End Payors allege Reckitt engaged in a product-hopping scheme to maintain Suboxone monopoly as brand-name exclusivity neared its end.
- Reckitt allegedly switched Suboxone from tablets to a film formulation, disparaged the tablet, and removed tablets from the market as generic competition approached.
- Plaintiffs claim Reckitt manipulated REMS and pursued a sham Citizen Petition to delay generic Suboxone approval.
- NDA approvals granted for Suboxone tablets (2002) and Suboxone film (2010); film is non-AB-rated to tablets, enabling a separate market.
- The alleged scheme is said to cause sustained higher prices and reduced competition, violating §2 of the Sherman Act and state consumer protection/unjust enrichment claims.
- The court analyzes Reckitt’s motions to dismiss the Direct Purchasers’ and End Payors’ complaints under Rule 8(a) and 9(b), applying a context-specific, drug-industry standard for antitrust claim viability.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Does product-hopping constitute exclusionary conduct under §2? | Plaintiffs allege exclusionary conduct by introducing a new product to undermine tablet competition. | Reckitt contends new product advances are procompetitive and do not foreclose competition. | Yes—plausible exclusionary conduct given market manipulation. |
| Does Suboxone film introduction and tablet removal injure competition? | Product-hopping and removal together foreclose the cost-efficient generic substitute. | Introduction of a new product is generally procompetitive; injury to competition not shown by film alone. | Plaintiffs plausibly alleged antitrust injury and Count II survives. |
| Does the SSRS/duty-to-deal framework support delaying generic entry under §355-1(f)(8)? | SSRS cooperation should prevent manipulation of the REMS process to delay approvals. | There is no general duty to deal; regulatory structure reduces need for antitrust intervention. | Count III dismissed—no duty to deal under current authority. |
| Are Counts IV–V (sham Citizen Petition and delayed filing) viable? | Petition was objectively baseless and aimed to interfere with competitors; injury shown. | Citizen Petition protections apply; not automatically a sham. | Counts IV–V survive; petition plausibly caused antitrust injury. |
| Do End Payors have standing to assert state-law claims? | End Payors have antitrust standing under AGC factors for states with Illinois Brick repealers. | Standing limited; many state claims should be dismissed for lack of injury in those states. | End Payors have antitrust standing in repealer states; many state-law claims dismissed for lack of standing. |
Key Cases Cited
- United States v. Grinnell Corp., 384 U.S. 563 (1966) (establishes monopoly-power elements and exclusionary conduct standard)
- Verizon Communications Inc. v. Law Offices of Curtis V. Trinko, LLP, 540 U.S. 398 (2004) (no general duty to deal; regulatory context may limit antitrust duties)
- Aspen Skiing Co. v. Aspen Highlands Skiing Corp., 472 U.S. 585 (1985) (refusal-to-deal exception to antitrust immunity based on longstanding course of dealing)
- United States v. Microsoft Corp., 253 F.3d 34 (2001) (court-wide antitrust framework for analyzing anticompetitive effects of conduct)
- Queen City Pizza, Inc. v. Domino’s Pizza, Inc., 124 F.3d 430 (1997) (monopoly power market definition standards under plausible market boundaries)